Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

NO_LONGER_AVAILABLE

Conditions studied: Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer

In brief

This is an expanded access protocol to allow continued maintenance therapy with ABT-888 (veliparib) for three patients with metastatic triple negative breast cancer who are currently receiving the investigational product in association with clinical trial participation. Additionally, the protocol will enroll up to 7 new patients with metastatic BRCA associated or triple negative breast cancer to allow for additional access to veliparib monotherapy, or at the investigator's discretion, veliparib in combination with cisplatin and/or vinorelbine.

Key facts

Study ID

NCT02985658

Run by

University of Washington

Last updated by the study team

2021-07-21

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Seattle Cancer Care Allliance — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.